Eastern Virginia School of Medicine Unlike cancers of the bladder, prostate, and kidney, where metastases to regional
lymph nodes portend incurable disease, penile tumors - like testicular cancers -
may sometimes be cured by a regional lymphadenectomy. Approximately half of the patients
presenting with penile cancers will have enlarged inguinal nodes. Since infection
is often present, differentiation of inflammatory nodes from those involved with
tumor metastases is frequently challenging. Thirty to 50 per cent of patients with
palpable nodes will actually have metastatic cancer.4,5 More problematic
are the 20 per cent of patients with clinically negative groin nodes at diagnosis
who have occult metastatic disease.1 Without treatment, patients with metastatic tumor will die of their disease; no
spontaneous remission of penile carcinoma has been reported. Therapy of such metastases,
however, is prone to complications and frequently results in unpleasant side-effects:
penile and scrotal lyphedema and substantial edema of the lower limbs. Given the high risk of such complications, one of the challenges of managing patients
with penile cancers has been to determine which patients will benefit from inguinal
dissection while avoiding unnecessary inguinal lymphadenectomies in patients without
metastatic disease. The selection of those patients who should undergo ilioinguinal
groin surgery has been an area of controversy for many years. However, an improved
understanding of the natural history of penile carcinoma now permits a systematic
and effective approach to management of these patients, based on the stage and grade
of the primary penile lesion coupled with the status of the inguinal nodes at the
time of diagnosis.4,5,6 Until recently, staging of penile cancers was by the Jackson system, first described
in 1966 and outlined in table I.7 A TNM staging system was introduced
in 1972, and modified in 1987, and has become the standard system at present. This
system is summarized in table II.8,9 In addition to tumor staging, recent reports by Fraley, by Solsona, and by McDougal
document the importance of tumor grade in the prognosis of penile cancers.5,6,10
There is general consensus that patients presenting with superficial grade 1 lesions
and palpably negative inguinal nodes may be followed expectantly. Similarly, there
has been general agreement that patients with primary tumors of any stage and potentially
resectable inguinal nodes which remain enlarged following a course of antibiotic
therapy should undergo inguinal or ilioinguinal lymphadenectomy. Additionally, there
is consensus that fixed inguinal nodes (stage T4) presage unresectable and incurable
disease not amenable to surgical therapy.4,6 It is the patient who presents
with invasive tumor but with clinically negative inguinal nodes who has presented
the greatest therapeutic dilemma. Figure 1 summarizes our approach to the patient who
has undergone surgery of the primary lesion, and who is being considered for lymphadenectomy. Because lymph node enlargement and lymphangitis due to infection of the primary
tumor is common at the time of diagnosis, all patients with penile cancer should
receive 4 to 6 weeks of antibiotic therapy before undergoing inguinal lymphadenectomy.
At the completion of this course of treatment, the groins are carefully examined
for the presence of abnormal nodes. Thirty to 60 per cent of patients who present
with penile cancer have palpable inguinal nodes, and following antibiotic therapy,
half of these nodes will harbor metastases.11 When metastases are detected
clinically in one groin, contralateral metastases will be present in 60 per cent
of cases due to the crossover of lymphatics at the base of the penis.12
Consequently, in this situation contralateral inguinal lymphadenectomy should also
be performed. It is generally accepted that patients with grade I, non-invasive tumors and clinically
negative inguinal nodes may safely be managed expectantly if close follow-up with
careful groin examinations every 2 months for at least 2 years can be assured.5,6,13,14
Unreliable patients or others who cannot be followed adequately are best served by
prompt inguinal lymphadenectomy. Considerable debate has ensued over the years regarding
immediate or delayed lymphadenectomy in other patients with clinically negative groins.
There has been support for expectant management of patients with invasive (T2 - T4)
lesions and no palpable inguinal adenopathy, with surgical intervention undertaken
only when lymphadenopathy develops. This avoids the substantial morbidity associated
with groin dissection. In those patients who later develop clinically positive nodes,
delayed lymphadenectomy can provide cure in 30-50 per cent.12,15,16,17
However, recent series support immediate inguinal lymphadenectomy in these cases,
citing ultimate mortality rates of up to 20 per cent in patients who are followed
until they develop clinically positive nodes before undergoing inguinal exploration.5,6,12,15,16,17
It is clear that in many of these patients, a window of opportunity to provide a
cure has been lost. Prophylactic groin irradiation in patients having clinically negative groins has
been investigated, and the incidence of subsequent inguinal metastases was found
not to be reduced significantly by this treatment.12,18,19,20,21 Furthermore,
irradiation makes subsequent physical examination of the groins difficult, and markedly
increases problems with surgery and wound healing if a groin dissection later becomes
necessary. Radiation may have a palliative role in the treatment of patients with
unresectable disease, or in poor surgical candidates. In the event unilateral groin metastases develop some time after surgical treatment
of the primary, inguinal lymphadenectomy of only the involved groin is required.2
While this would seem to contradict the recommendations outlined above, bilateral
occult metastases which are present from diagnosis but which become do not become
clinically apparent until later should manifest themselves at about the same time.
Consequently, the absence of clinically detectable nodes on the side contralateral
to a late-developing groin metastasis suggests that the clinically negative nodes
were not involved from the outset. Preoperative staging of the pelvic, common iliac, and para-aortic nodes with CT
scan and, where indicated, with needle biopsy, is essential. While survival has followed
resection of tumor limited to the external iliac nodes, no patient with common iliac
or para-aortic metastases has survived.3 Fine needle aspiration of suspicious
nodes in these areas may confirm metastatic tumor and thus avoid unnecessary surgery.
The most important predictor of ultimate survival continues to be primary tumor stage.6,24 Occasionally, palliative groin dissection is performed even in the face of extensive
regional or distant metastases. Lymphadenopathy which threatens to erode through
the inguinal skin or invade into the femoral vessels may need to be removed to avoid
pain, inguinal infection, or serious hemorrhage. The concept of the sentinel node was proposed by Cabanas, and
postulates that there is a node or group of nodes - lying between the superficial
external pudendal vein and the superficial epigastric vein - where the earliest metastasis
from a penile tumor will occur consistently (fig. 2).22,23
A negative sentinel node biopsy in the presence of clinically negative groins was
felt to indicate that further inguinal dissection was unnecessary. Five-year survivals
of 90 per cent have been reported in this setting. However, subsequent reports of
the development of metastases following a negative sentinel node biopsy have suggested
that sentinel node biopsy is not reliable.24,25,26,27 While further evaluation
of this technique continues, most large centers treating penile cancer are no longer
using it. Sentinel node biopsy is not appropriate in the presence of clinically suspicious
nodes; rather full superficial and deep inguinal dissections should be performed.
When the sentinel node biopsy is performed, the incision should be placed so that
if a full formal inguinal lymphadenectomy is later required, the original sentinel
node biopsy incision can be excised with the lymphadenectomy specimen. Despite the encouraging prognosis for many patients with inguinal metastases who
undergo inguinal or ilioinguinal lymphadenectomy, there has been a longstanding reluctance
on the part of surgeons to subject patients to this procedure because of the 30 to
50 per cent incidence of major morbidity associated with it.17,19,28,29
Complications include: lymphocoele, substantial lower limb lymphedema, skin loss,
and infection. Skin flap necrosis can be minimized by selecting the appropriate incision,
by careful tissue handling, by careful attention to skin flap thickness with excision
of ischemic flap margins, and by transposing the head of the sartorius muscle to
cover the defect left over the femoral vessels. Use of intravenous fluorescein dye
and a Woods' lamp intraoperatively to assess viability of wound edges is a useful
adjunct.30 Lower limb lymphedema can be reduced by careful attention to
intraoperative ligation of lymphatics, by immobilization of the limb or limbs in
the postoperative period, and by suction drainage of the lymphadenectomy site. Elastic
support hose should be used in the immediate postoperative period and may be required
long term in many patients. Wound infection can be minimized by intensive preoperative
antibiotic therapy to reduce infection and inflammation from the primary, and by
the use of prophylactic antibiotics.35 Thrombotic problems may be avoided
through the use of subcutaneous heparin in the perioperative period, particularly
when the classical inguinal and pelvic dissection is combined with prolonged bed
rest postoperatively. Figure 3 shows the various incisions described for
inguinal and ilioinguinal lymphadenectomy. We prefer the oblique incision below and
parallel to the inguinal crease because it maintains the integrity of the inguinal
ligament, and because it preserves the cutaneous blood supply which runs parallel
to the inguinal ligament (figs. 3B,C). The indications for inguinal and ilioinguinal lymphadenectomy are outlined in
figure 1. When the lesion is stage Tis, To, or T1, the
tumor is of low grade (grade 1), the groins are negative, and the patient can be
relied upon to participate in a program of close follow-up, we observe the patient
with bimonthly exams for at least two years.31 Similarly, if the lesion
is of low grade at diagnosis and the inguinal nodes are enlarged but normalize following
antibiotic therapy, we will follow the patient expectantly. If the tumor demonstrates invasiveness (stage > T2) or is of high histologic
grade (grade 2 or 3), and the groins are negative or normalize following antibiotic
therapy, we recommend a modified bilateral superficial inguinal dissection with frozen
section evaluation similar to that described by Catalona.32
If these nodes are negative, we close and follow the patient expectantly as outlined
above. If these nodes are positive, we proceed with a classical inguinal lymphadenectomy,
extending the limits of the groin dissection to those illustrated in fig.
4, and including a bilateral pelvic node dissection. Metastasis to the pelvic nodes in the absence of inguinal node metastases is an
extremely rare event and has not been observed in many modern series.5, 14,
23 In the setting of negative superficial and deep inguinal lymphadenectomies
and a negative pelvic CT scan, pelvic lymphadenectomy is not required. If bilateral palpable inguinal nodes persist following antibiotic therapy, we
proceed with bilateral ilioinguinal lymphadenectomy, using the classical limits of
dissection, except for the inferolateral quadrant, where experience has shown there
to be few lymph nodes. In the event one groin normalizes following antibiotic therapy,
but the other remains abnormal, we proceed with a superficial inguinal dissection
on the clinically normal side with frozen section evaluation. If positive, a full
inguinal dissection is carried out. If this is negative, we proceed with a full ilioinguinal
dissection on the contralateral abnormal side. Generally, pelvic node dissection
is done through a low midline incision giving access to both right and left pelvic
node groups (fig. 3B). The dissection technique for
this part of the operation is familiar to urologists, as it is similar to that used
in bladder cancer staging, except that the dissection of the external iliac nodes
is carried more distally under the inguinal ligament to include all iliac and deep
inguinal nodes there. If only one groin is involved, a unilateral pelvic node dissection
may be done through an oblique low abdominal incision (fig.
3C) and may provide some diminished patient morbidity.33 While some patients with clinically negative groins will have impalpable metastatic
disease, the majority will not.22,32 This fact, coupled with the morbidity
associated with the classical inguinal lymphadenectomies described by Daseler and
Baranofsky, has made surgeons reluctant to subject patients to these procedures,
even when tumor characteristics indicate that lymphadenectomy would be advisable.34,35
Both Catalona and Puras and associates have described modifications of the classical
dissection which are aimed at reducing many of the unpleasant sequelae of the classical
operation.32,36 All patients are treated with 4 to 6 weeks of oral broad-spectrum antibiotics
following excision of the primary tumor. A clear liquid diet the day prior to surgery
is prescribed, and the patient is given cleansing enemas the night before surgery.
Antiembolism compressive stockings are used. The patient is placed in a supine position after spinal anesthesia is first administered.
A foley catheter is placed to straight drainage. The scrotum and penis are then retracted
out of the field and draped off. The legs are then abducted and
externally rotated to best expose the anteromedial thigh and groin. A pillow is placed
beneath the knees for support. A 6 to 8-cm incision is then made 3 to 4-cm below
the inguinal ligament and parallel to it (fig. 5A).
The incision is carried down to Scarpa's fascia. Gentle sponge traction is used to
separate the skin edges (fig. 5B). The subcutaneous
tissue in Camper's layer is carefully preserved, and meticulous handling of these
tissues and the skin edges must be observed throughout. Stay sutures of 2-0 or 3-0
silk and the use of skin hooks are helpful in avoiding injury to the wound edges. The saphenous vein and its tributaries are identified, and the superficial areolar
and node-bearing tissue is gently dissected off the vein downward to the fascia lata
(fig. 5C). The venous branches emptying into the saphenous
vein are carefully ligated and divided. The saphenous vein is preserved (fig.
5D). Particular attention is paid the tissue superomedial to the saphenous vein
around the superficial epigastric vein, as this is the area of the sentinel node
tissue. Large lymphatics and small venous branches must be carefully and meticulously
ligated or fulgerated. The dissection is carried superiorly to approximately 2-cm
cephalad to the inguinal ligament where it is carried down to the fascia of the external
oblique muscle (fig. 5E). Dissection is next carried inferiorly to about 4-cm below the incision. In the
Catalona operation, the lower limit of dissection is the lower border of the fossa
ovalis (fig. 5F). We, as well as Puras and associates,
carry our dissections slightly lower, although there is not much superficial nodal
tissue in this area. The specimen of superficial nodal tissue is oriented, labeled
by quadrant (fig. 6), and sent for frozen section evaluation
.37 If the nodes are negative, the wound is thoroughly irrigated with sterile water
and closed in layers, taking care to eliminate any potential spaces. A closed suction
drainage system is placed (fig. 5H) and remains for
5 to 7 days during which time the patient is maintained at complete bed rest. When positive nodes are present or metastatic disease is confirmed by frozen section
during a limited inguinal dissection, a classic radical inguinal lymphadenectomy
is performed.33 An incision of 6 to 8-cm is made parallel to the inguinal
ligament and about 3 to 4-cm inferior to it. The incision is carried down to Scarpa's
fascia, and the saphenous vein is identified. This is ligated with 2-0 silk sutures
and divided. The superficial nodal tissue is systematically mobilized, beginning
in the superomedial quadrant, freeing the tissue towards the junction of the saphenous
vein with the femoral vein at the fossa ovalis. The sentinel node tissue is identified
and tagged with a suture. This dissection is extended above the inguinal ligament
2-cm, and the limits of the standard dissection, as outlined in figure
4, are utilized. Next, the venous tributaries of the saphenous vein are meticulously ligated and
divided as well as any large lymphatics. The saphenous vein carefully dissected down
to the fossa ovalis and the junction with the femoral vein is identified, clamped,
divided and ligated. The fascia lata is opened and excised with all the nodal tissue
superficial to it. This exposes the femoral sheath and Scarpa's triangle. The lateral
aspect of this dissection is the medial border of the sartorious, and the medial
border the of the adductor longus is the medial side. The femoral sheath is opened from the inguinal ligament to
the apex of the femoral triangle. Within the sheath are the femoral vein, the femoral
artery lateral to it, and fatty areolar tissue containing the
deep inguinal nodes medially (fig. 7). The femoral nerve
is lateral to the artery and is not encountered in the usual dissection (fig.
8A). The vein is gently retracted laterally to allow dissection of tissue from
the lateral and anterolateral aspect of the vein, and nodal and areolar tissue is
dissected from the anterior artery and between the artery and vein. The nodes are
dissected to below the inguinal ligament, to the node of Cloquet (or Rosenmuller),
the most proximal of the deep inguinal chain. One to 5 nodes are usually encountered.
About 5 to 8-cm below the inguinal ligament, the profunda femoris artery arises on
the lateral aspect of the femoral artery. This must be carefully dissected and preserved,
especially if myocutaneous flap coverage may later be required. The wound is then irrigated carefully and careful attention is given to all bleeders
and lymphatics. The sartorious muscle is separated sharply from its origin on the
anterior superior iliac spine and mobilized medially to cover the now exposed femoral
vessels (fig. 8B).34,36 Drainage using a
closed suction catheter apparatus is placed, and the wound is carefully closed in
layers. Several sutures are used to secure Camper's fascia to the anterior aspect
of the muscles to close potential space and discourage lymphocoele formation (fig. 8C).37 The skin edges are carefully assessed,
using intravenous fluorescein and the Woods' lamp if necessary, and any questionably
viable skin excised. The wound is then meticulously closed in layers (fig.
8D). The patient is maintained at complete bed rest with compressive stockings
in place for 5-7 days. Subcutaneous heparin is administered. The foley catheter is
discontinued after 24-48 hours. Closed suction is maintained for 5 days. Squamous cell carcinoma is characterized by aggressive local invasion into surrounding
tissues. Large inguinal nodes, particularly when presenting for treatment late or
following an extended period of neglect, will have invaded the overlying skin of
the groin and may ulcerate through it in extreme cases. Induration of the skin is
suggestive of such local invasion. In this setting, the tumor is excised leaving
a 2-cm margin of normal skin around the indurated or ulcerated area. A radical ilioinguinal
lymphadenectomy is performed, and all tumor is completely resected. In some instances, there may be involvement of the femoral vessels, particularly
the vein. Resection of the anterior wall of the vein with reconstruction using a
saphenous vein graft or Gore-tex patch may be required.36 In some instances
of severe involvement, the vein may be ligated and excised. Large skin defects may be closed with a tensor fascia lata or gracilis myocutaneous
graft.38,39 Such a graft may be based over the hip and swung medially
and superiorly to cover a groin defect. Again, all postoperative precautions recommended
for the classical radical lymphadenectomy should be employed for patients undergoing
this procedure. Pizzocaro and associates have reported their experience with adjuvant vincristine,
bleomycin, and methotrexate (VBM) in the treatment of 25 patients with squamous carcinoma
of the penis undergoing ilioinguinal lymphadenectomy. Relapse occurred in only 4
patients (16 per cent), with a 5-year disease-free survival of 82 per cent.40
Five-year disease free survival in an earlier series of 31 similar patients treated
with surgery alone was 37 per cent. All relapses in the treated group occurred in
patients with bilateral disease, and no relapse occurred in any of the 9 patients
with only a single node involved. This study suggests both that patients with multiple
nodal metastases, bilateral nodal involvement or positive pelvic nodes may benefit
from adjuvant therapy, while patients with minimal metastatic disease may not need
such treatment. Several authors have also reported experience with cis-platinum based therapies
for the treatment of primary or recurrent fixed nodal metastases.41,42,43,44
Of a composite group of 29 patients, objective response was noted in 66 per cent
(19 patients) and 11 (38 per cent) could be resected. Five patients remain disease
free at 12-57 months. Use of the VBM protocol in 13 patients with fixed nodal metastases
allowed resection of disease in 5 patients of whom 2 (15 per cent) are alive at 5
and 13 years. Three of this group and 3 previously untreated patients were given
a regimen of cis-platinum and 5-fluorouracil. Five of the 6 achieved partial remission
and 4 could be completely resected. Three of the 4 are alive and disease-free at
3, 8, and 10 years. Neoadjuvant chemotherapy allowed 9 (56 per cent) of the overall
group of 16 to be resected, and appears to have cured 5 (31 per cent).45,46 2.0 Conclusions Surgery remains the primary treatment for squamous cell carcinoma of the penis,
although combined approaches using chemotherapy and surgery are promising. Recent
experience appears to confirm that an aggressive surgical approach utilizing immediate
inguinal or ilioinguinal lymphadenectomy will improve survival in high-risk patients.
Patients with low-grade, non-invasive disease and clinically negative groins who
can be relied on to comply with follow-up may be followed expectantly. Patients having
enlarged or suspicious nodes should undergo 6 weeks of antibiotic therapy followed
by careful re-evaluation, and any residual suspicious inguinal nodes should be resected.
High-risk patients, those with clinically negative groin nodes but grade II or III
tumor or evidence of corporal invasion, should undergo immediate modified inguinal
dissection, with full dissection if frozen section reveals metastatic tumor. Some
patients with fixed inguinal nodal metastases may respond to neoadjuvant chemotherapy
sufficiently to allow inguinal lymphadenectomy. Radiation therapy is not indicated
for primary treatment nor helpful for adjuvant therapy, but may be useful as a palliative
measure in late-stage unresectable disease.

ARTICLES
Surgical Management of Squamous Cell Carcinoma of the Penis
Norfolk, Virginia
Although squamous carcinoma of the penis is a rare disease in the
United States, it is a significant health problem in some South American and African
countries, where it may account for up to 20 per cent of male cancers.1,2
Metastases from penile cancers spread by way of the penile lymphatics to the regional
nodes, specifically the superficial and deep inguinal nodes, and subsequently the
external iliac and obturator nodes within the pelvis. Involvement of the regional
nodes with tumor is, in fact, the best predictor of long-term survival in patients
with carcinoma of the penis.3
1.1 Staging and Grading
1.2 Considerations in Inguinal and Ilioinguinal Lymphadenectomy
1.3 Sentinel Node Biopsy
1.4 Avoiding Complications from Inguinal Lymphadenectomy
1.5 Technique of Inguinal Lymphadenectomy
1.51 Modified Inguinal Lymphadenectomy
1.52 Classic Inguinal Lymphadenectomy (after Daseler)
1.53 Management of Enlarged or Ulcerated Nodes and Femoral Vessel Involvement
1.54 Adjuvant and Neoadjuvant Chemotherapy
1. Persky L, deKernion J: Carcinoma of the penis. CA 1986; 36: 258-273.
2. Ornellas AA, Seixas AL, Morota A etal: Surgical treatment of invasive squamous
cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 1994; 151:
1244-1249.
3. deKernion JB, Tynbery P, Persky L, et al: Carcinoma of the penis. Cancer 1973;
32: 1256-1262.
4. Horenblas S, Van Tinteren H, Delamarre JFM, et al: Squamous cell carcinoma of
the penis - III. Treatment of regional lymph nodes. J Urol 1993; 149: 492-497.
5. Fraley EE, Zhang G, Manuvel C, Niehans GA: The role of ilio-inguinal lymphadenectomy
and significance of histological differentiation in treatment of carcinoma of the
penis. J Urol 1989; 142: 1478-1482.
6. McDougal WS: Carcinoma of the penis: Improved survival by early regional lymphadenectomy
based on the histological grade and depth of invasion of the primary lesion. J Urol
1995; 154: 1364-1366.
7. Jackson SM: The treatment of carcinoma of the penis. Br J Urol 1966; 53: 33-35.
8. Union Internationale Contre le Cancer (UICC): TNM Classification of malignant
tumors, 2d ed. Geneva: Imprimerie G. de Buren SA, 1974.
9. Union Internationale Contre le Cancer (UICC): TNM atlas: Illustrated guide to
the TNM/pTNM Classification of malignant tumors, 3d ed. New York: Springer-Verlag,
1989: 237-244.
10. Solsona E, Jborra J, Ricos JV, et al.: Corpus cavernosum invasion and tumor grade
in the prediction of lymph node metastases. Eur Urol 1992; 22: 115-118.
11. Johnson DE, Lo RK: Management of regional lymph nodes in penile carcinoma: Five-year
results following therapeutic groin dissections. Urology 1984; 24: 352-355.
12. Ekstrom T, Edsmyr F: Cancer of the penis: A clinical study of 229 cases. Acta
Chir Scand 1958; 115: 25-29.
13. McDougal WS, Kirchner FK Jr, Edwards RH, et al: Treatment of carcinoma of the
penis: The case for primary lymphadenectomy. J Urol 1986; 136: 38-42.
14. Srinivas V, Morse MJ, Herr HW, et al: Penile cancer: relation of extent of nodal
metastases to survival. J Urol 1987; 137: 880-886.
15. Catalona WJ: Role of lymphadenectomy in carcinoma of the penis. Urol Clin NA
1980; 7: 85-89.
16. Beggs JH, Spratt JS Jr: Epidermoid carcinoma of the penis. J Urol 1964; 91: 166-169.
17. Fossa SD, Hall KS, Johanssen MB: Carcinoma of the penis: Experience at the Norwegian
Radium Hospital: 1974-1985. Eur Urol 1987; 13: 372-376.
18. Murrell DS, Williams JL: Radiotherapy in the treatment of carcinoma of the penis.
Brit J Urol 1965; 37: 211-214.
19. Jensen MS: Cancer of the penis in Denmark: 1942 to 1962 (511 cases). Danish Med
Bull 1977; 24: 66-70.
20. Staubitz WJ, Melbourne HL, Oberkircher OJ: Carcinoma of the penis. Cancer 1955;
8: 371-374.
21. Ravi R: Morbidity following groin dissection for penile carcinoma. Br J Urol
1993; 72: 941-45.
22. Riveros M, Garcia R, Cabanas RM: Lymphangiography of the dorsal lymphatics of
the penis: technique and results. Cancer 1967; 20: 2026-2031.
23. Cabanas RM: An approach for the treatment of penile carcinoma. Cancer 1977; 39:
456-459.
24. Perinetti EP, Crane DC, Catalona WJ: Unreliability of sentinel node biopsy for
staging penile carcinoma. J Urol 1980; 124: 734-738.
25. Wespes E, Simon J, Schulman CC: Cabanas approach: Is sentinel lymph node biopsy
reliable for staging penile carcinoma? Urology 1986; 28: 278-282.
26. Fowler JE Jr: Sentinel node biopsy for staging penile cancer. Urology 1984; 23:
352-356.
27. Pettaway CA, Pisters LL, Colin PN, et al: Sentinel lymph node dissection for
penile carcinoma: the MD Anderson Cancer Center experience. J Urol 1995; 154: 1999-2003.
28. Skinner DG, Leadbetter WF, Kelley SB: The surgical management of squamous cell
carcinoma of the penis. J Urol 1972; 107: 273-279.
29. Hardner GJ, Bhanalaph T, Murphy GP et al: Carcinoma of the penis: Analysis of
therapy in 100 consecutive cases. J Urol 1972; 108: 428-432.
30. Smith JA, Middleton RG: The use of fluorescein in radical inguinal lymphadenectomy.
J Urol 1979; 122: 754-758.
31. Lynch DF, Schellhammer PF: Tumors of the penis. In Walsh PC, Retik AB, Stamey
TA, Vaughan ED (eds): Campbell's Urology, 7th ed., Philadelphia, WB Saunders Co.,
in press.
32. Catalona WJ: Modified inguinal lymphadenectomy for carcinoma of the penis with
preservation of the saphenous veins: Technique and preliminary results. J Urol 1988;
140: 306-311.
33. Fowler JE: Mastery of Surgery: Urology. Boston, Little, Brown Co., 1991.
34. Spratt JS Jr, Shieber W, Dillard BM: Anatomy and Surgical Techniques of Groin
Dissection. St Louis, CV Mosby, 1965.
35. Daseler E, Anson B, Riemann A: Radical excision of the inguinal and iliac lymph
nodes. Surg Gynecol Obstet 1948; 87: 679-684.
36. Baranofsky ID: Technique of inguinal node dissection. Surgery 1948; 24: 555-561.
37. Puras A, Rivera J: Inguinal and pelvic lymphadenectomy for penile cancer. Atlas
Urol Clin NA 1995; 3: 81.
38. Hill HL, Nahai F, Vasconez LO: The tensor fascia lata myocutaneous free flap.
Plast Reconstr Surg 1978; 61: 517-521.
39. McCraw JB, Dibbell DG, Carraway JH: Clinical definition of independent myocutaneous
vascular territories. Plast Reconstr Surg 1977; 60: 341-345.
40. Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate
for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 1988;
27: 823-827.
41. Hussein AM, Benedetto P, Sridar KS: Chemotherapy with cisplatin and 5-fluorouracil
for penile and urethral squamous cell carcinoma. Cancer 1990; 433: 65-69.
42.Shammas FV, Ous S, Fossa SD: Cisplatin and 5-fluorouracil and advanced cancer
of the penis. J Urol 1992; 630: 147-151.
43. Dexeus FH, Logothetis CJ, Sella A et al: Combination chemotherapy with methotrexate,
bleomycin, and cisplatin for advanced squamous cell cercinoma of the male genital
tract. J Urol 1991; 146: 1284-1288.
44. Kattan J, Culine S, Droz JP et al: Penile cancer chemotherapy: twelve year's
experience at Institut Gustave-Roussy. Urology 1993; 42: 559-563.
45. Fisher HAG, Barada JH, Horton J, et al: Neoadjuvant therapy with cisplatin and
5-fluorouracil for stage III squamous cell carcinoma of the penis. J Urol 1990; 143:
352A (abstr 653).
46. Pizzocaro G, Piva L, Nocolai N: Lymphadenectomy for cancer of the penis. In:
Donohue JP (ed), Lymph Node Surgery in Urology, Oxford, Isis Medical Media, 1995;
p 118- 130.